Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kammula Website

Udai S. Kammula, M.D.

Selected Publications

1)  Bartlett EK, Fetsch P, Filie AC, Abati A, Steinberg SM, Wunderlich JR, White DE, Stephens DJ, Marincola FM, Rosenberg SA, Kammula US.
Human Melanoma Metastases Demonstrate Non-Stochastic Site-Specific Antigen Heterogeneity that Correlates with T Cell Infiltration.
Clin. Cancer Res. 2014.
2)  Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, Perron RM, Werner CD, Phan GQ, Kammula US, Kebebew E, Pacak K, Chen KY, Celi FS.
Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans.
Cell Metab. 19: 302-9, 2014.
3)  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
A novel nomogram for peritoneal mesothelioma predicts survival.
Ann. Surg. Oncol. 20: 555-61, 2013.
4)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
5)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
J. Clin. Oncol. 31: 2152-9, 2013.
6)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
7)  Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Clin. Cancer Res. 18: 2039-47, 2012.
8)  Langan RC, Ripley RT, Davis JL, Prieto PA, Datrice N, Steinberg SM, Bratslavsky G, Rudloff U, Kammula US, Stojadinovic A, Avital I.
Liver directed therapy for renal cell carcinoma.
J Cancer. 3: 184-90, 2012.
9)  Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US.
Minimally invasive liver resection to obtain tumorinfiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
World J Surg Oncol. 10: 113, 2012.
10)  Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CR, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.
The stoichiometric production of IL-2 and IFN-g mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Sci Transl Med. 4: 149ra120, 2012.
11)  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy.
Clin Cancer Res. [Epub ahead of print], 2011.
12)  Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, Avital I.
Liver Resection and Ablation for Metastatic Adrenocortical Carcinoma.
Ann Surg Oncol. [Epub ahead of print], 2011.
13)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011.
14)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
15)  Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich J, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot C, Rosenberg SA.
CD8+ enriched.
Clin Cancer Res. [Epub ahead of print], 2010.
16)  Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM.
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
J. Immunother. 33: 626-9, 2010.
17)  Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I.
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
Ann. Surg. Oncol. 17: 163-70, 2010.
18)  Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA.
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
J. Immunother. 33: 828-33, 2010.
19)  Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CR, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, Vanwaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.
Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood. [Epub ahead of print], 2009.
20)  Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, Quezado M, Goldspiel BR, Venkatesan A, Berger A, Walker M, Toomey MA, Steinberg SM, Giaccone G, Rosenberg SA, Avital I.
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Trials. 10: 121, 2009.
21)  Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
J. Clin. Oncol. 26: 5233-9, 2008.
22)  Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S.
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
Cancer. 113: 293-301, 2008.
23)  Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA.
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clin. Cancer Res. 14: 5610-8, 2008.
24)  Kammula US, Serrano OK.
Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy.
J Transl Med. 6: 60, 2008.
25)  Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA.
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
J. Immunother. 30: 825-30, 2007.
26)  Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA.
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
Clin. Cancer Res. 13: 6681-8, 2007.
27)  Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE.
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
J. Immunother. 29: 224-31, 2006.
28)  Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes.
Science. [Epub ahead of print], 2006.
29)  Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
J. Clin. Oncol. 24: 2283-9, 2006.
30)  Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA.
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
J. Immunother. 29: 455-63, 2006.
31)  Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR.
Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.
Cancer Lett. [Epub ahead of print], 2006.
32)  Kammula US.
Predicting outcomes after percutaneous ethanol injection for small hepatocellular cancer.
Cancer J. 12: 175-7, 2006.
33)  Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW.
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.
Cancer Cell. 10: 99-111, 2006.
34)  Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J Clin Oncol. 23: 2346-57, 2005.
35)  Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
J Clin Oncol. 23: 6043-53, 2005.
36)  Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM.
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J Immunother. 28: 593-8, 2005.
37)  Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM.
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma.
J Immunol. 175: 6169-76, 2005.
38)  Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA.
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Ann. Surg. Oncol. 12: 1005-16, 2005.
39)  Kammula US, Ghossein R, Bhattacharya S, Coit DG.
Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients.
J Clin Oncol. 22: 3989-96, 2004.
40)  Thurber SE, Khong HT, Kammula US, Rosenberg SA.
Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.
J Immunother. 25: 63-71, 2002.
41)  Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM.
Short-term kinetics of tumor antigen expression in response to vaccination.
J Immunol. 167: 1809-20, 2001.
42)  Kammula US, Buell JF, Labow DM, Rosen S, Millis JM, Posner MC.
Surgical management of benign tumors of the liver.
Int J Gastrointest Cancer. 30: 141-6, 2001.
43)  Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM.
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
J Immunol. 164: 495-504, 2000.
44)  Kammula US, Marincola FM, Rosenberg SA.
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.
J Natl Cancer Inst. 92: 1336-44, 2000.
45)  Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diez A, Lee KH, Kammula U, Rosenberg SA, Marincola FM.
Status of activation of circulating vaccine-elicited CD8+ T cells.
J Immunol. 165: 2287-96, 2000.
46)  Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM.
Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes.
Int J Cancer. 86: 818-26, 2000.
47)  Schwartz GN, Kammula U, Warren MK, Park MK, Yan XY, Marincola FM, Gress RE.
Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
Stem Cells. 18: 331-42, 2000.
48)  Kammula US, Marincola FM.
Cancer immunotherapy: is there real progress at last?.
BioDrugs. 11: 249-60, 1999.
49)  Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP.
Cancer therapy using a self-replicating RNA vaccine.
Nat Med. 5: 823-7, 1999.
50)  Riker AI, Panelli MC, Kammula US, Wang E, Wunderlich J, Abati A, Fetsch P, Rosenberg SA, Marincola FM.
Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma.
Cancer Detect Prev. 23: 387-96, 1999.
51)  Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM.
Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens.
J Immunol. 163: 6867-75, 1999.
52)  Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S, Marincola F.
Immune selection after antigen-specific immunotherapy of melanoma.
Surgery. 126: 112-20, 1999.
53)  Kammula US, White DE, Rosenberg SA.
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Cancer. 83: 797-805, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 3/28/2014.